Name, botanical identity, and plant-part boundary
Fleeceflower caulis, called Shou wu teng or Ye jiao teng, is the dried vine stem of a plant in Polygonaceae. The currently accepted botanical name is commonly given as Pleuropterus multiflorus (Thunb.) Turcz. ex Nakai, while pharmacopoeias, papers, and product records often retain the synonym Polygonum multiflorum Thunb. An extract should come from traceable vine stem, not be identified merely by the words “He Shou Wu.”
The tuberous root of the same plant is used as raw or processed He Shou Wu, and its leaves, twigs, stems, and roots differ in tissues and constituent proportions. Efficacy claims, doses, and liver-injury cases concerning root products cannot be transferred directly to the caulis. Conversely, lower levels in stems cannot establish that any root preparation is safe. Similar-looking vines from other species must also be excluded.
In WSIC this entry is coded 3.1.2, under “Category 3 Consumer Products and Content / Functional Foods / Botanical Extract Supplements.” Classification describes the product’s location; it does not validate claims to induce sleep, provide sedation, or treat insomnia. Dried herb, decoction, granules, concentrated extract, enriched fraction, isolated compound, and multi-herb formula are distinct interventions and cannot share conclusions.
Constituents, extraction, and batch variation
Reported constituents include stilbene glycosides, anthraquinones, flavonoids, and other metabolites. Quality studies frequently measure 2,3,5,4′-tetrahydroxystilbene-2-O-beta-D-glucoside (THSG), emodin, and physcion. These are chemical markers rather than the complete active fraction, and none alone demonstrates a sleep benefit or safety. Vine age and diameter, origin, harvest, drying, and storage may all alter the profile.
Water extraction more closely resembles traditional decoction, whereas ethanol concentration, temperature, time, particle size, solvent ratio, and concentration method change the recovery of polar compounds and anthraquinones. Matching total flavonoids, total glycosides, or one chromatographic peak does not ensure that the remaining composition or exposure matches. A purified fraction or isolated compound used in research is not interchangeable milligram for milligram with an ordinary water-extract powder.
Stilbene glycosides can occur as cis and trans forms whose proportions may change with light, heat, and processing; free and bound anthraquinones should also be distinguished. A “10:1” claim is verifiable only with starting-material input, dry-extract yield, carrier proportion, and marker recovery. A useful certificate states methods, measured amount per serving, batch range, and end-of-shelf-life specification instead of only a promotional standardization percentage.
Product specifications, dose, and comparability
A suitable label identifies the accepted or verifiable pharmacopoeial name, vine-stem part, extraction solvent, extract ratio or herb equivalent, extract mass per serving, marker range, excipients, lot, and warnings. Labels that say only “Fo-ti,” “He Shou Wu,” or “Polygonum extract” blur the boundary between stem and root. The English words caulis or vine cannot substitute for supply-chain authentication.
Traditional doses for pharmacopoeial crude herb apply to a defined identity, preparation, and decoction process; they are not established effective or safe doses for every concentrated supplement. Animal studies often administer crude-herb equivalents, total flavonoids, or isolated compounds per kilogram and use pentobarbital or chemically induced sleep disturbance. Simple body-weight conversion cannot produce a daily human capsule dose, and no reliable human sleep trial has established a general dose range.
If use continues after review by a physician or pharmacist, only one authenticated product should be changed at a time, with the lot, serving, timing, sleep diary, concomitant medicines, alcohol, and adverse events recorded. Crude herb, granules, formulas, and several “He Shou Wu” supplements should not be stacked and then treated as a single exposure. Personal experience cannot replace evaluation of abnormal liver tests or persistent insomnia.
Sleep evidence and its limits
An older animal study reported sleep-related changes with a caulis preparation in a mouse pentobarbital experiment and rat sleep recordings, using very high crude-herb equivalents. It does not establish absorption, effective dose, or long-term safety for a modern commercial human extract. Potentiation of pentobarbital and changes in rodent slow-wave sleep are not equivalent to improving deep sleep or insomnia in people.
Later mouse work examined glycoside, anthraquinone, and flavonoid fractions, while recent chemically induced sleep-disturbance studies have associated total flavonoids or isolated compounds with sleep latency, duration, and neural signals. These experiments can nominate constituents and hypotheses, but the preparations are not standardized across studies and some depend on sedative-drug interaction. They cannot be pooled into a confirmed treatment effect.
Multi-herb formulas containing the caulis, herb pairs with Albiziae Cortex, and traditional clinical prescriptions cannot attribute an observed change to this ingredient alone. No completed randomized, placebo-controlled trial of a botanically authenticated and chemically characterized single-ingredient caulis extract in people with insomnia was identified. It therefore cannot replace cognitive behavioral therapy for insomnia, assessment for sleep apnea, or evidence-based medication when indicated.
Mechanistic hypotheses and outcome assessment
Animal and laboratory reports involve GABA, serotonin receptors, prostaglandin D2, inflammatory signaling, and other neural pathways, but their findings depend on the model, fraction, and dose. Receptor-expression changes or molecular docking do not show that an orally consumed mixture reaches the same target in the human brain. Antioxidant or anti-inflammatory activity does not automatically become a sleep effect.
Evaluation should distinguish sleep-onset latency, wake after sleep onset, total sleep time, sleep efficiency, perceived restoration, and next-day function in advance. Loss of righting reflex, drug-induced sleep prolongation, rat electroencephalographic slow waves, and human polysomnography are not equivalent outcomes. An “effective rate,” a one-night wearable score, or an uncontrolled before-and-after change cannot remove expectancy, natural variability, or concurrent schedule changes.
Future human trials should use vine-stem extract authenticated by morphology, DNA, and chemical fingerprinting; disclose solvent, yield, and batch measurements for THSG and anthraquinones; use an appearance-matched placebo; and preregister primary outcomes. Liver measures, gastrointestinal events, concomitant medicines, and post-discontinuation changes also require systematic reporting. Persistent insomnia with choking snoring, unusual sleep behavior, marked daytime sleepiness, or emotional crisis warrants clinical care first.
Safety, liver risk, and special populations
Fleeceflower caulis should not be assumed free of liver risk because it is a stem. An animal study directly comparing water extracts of caulis, raw root, and processed root found lower levels of some stilbene glycosides and emodin and milder idiosyncratic liver injury with caulis, yet the authors still warned of potential risk. Lower and milder do not mean zero risk in humans, and existing evidence cannot supply a reliable incidence.
Many clinical case series and reviews concern raw root, processed root, or formulas with unclear plant parts, so they cannot be used to calculate an incidence for caulis extract. They nevertheless show why correct labeling and exclusion of root material matter. Potential injury may depend on host susceptibility, immune state, dose, duration, processing, and multiple constituents; all cases cannot be assigned with certainty to emodin or any single stilbene glycoside.
People with prior liver disease, substantial alcohol intake, or other potentially hepatotoxic medicines or herbs should not self-experiment. Evidence is inadequate for pregnancy, lactation, children, and people with impaired liver or kidney function. Additive effects with hypnotics, alcohol, or other central depressants are uncertain, and anthraquinone-related constituents may contribute to gastrointestinal discomfort or diarrhea. Jaundice, dark urine, pale stool, marked fatigue, persistent nausea, itching, or right-upper abdominal pain requires immediate discontinuation and medical assessment.
Authentication, quality control, and compliance
Raw-material testing should confirm both species and vine-stem part using macroscopic or microscopic examination, thin-layer or high-performance liquid chromatography, reference material, and DNA barcoding as appropriate. A recent small market survey found substitution by a related species in many sampled products and failure to detect required analytes in some substitutes. Its percentage cannot be generalized to the whole market, but it shows why appearance, a common name, or one peak is insufficient for release.
DNA testing is strong for species questions, but heavy processing can degrade DNA and DNA alone cannot prove stem rather than root from the same plant. Chemical fingerprints and multi-marker quantification add composition and part evidence, but may be defeated by spiking. A stronger program combines traceability, morphology or microscopy, DNA, THSG and anthraquinone measurements, and a broad fingerprint rather than treating a particular vine-diameter range as the sole authenticity rule.
Finished products also need use- and jurisdiction-appropriate testing for moisture, microorganisms, mycotoxins, pesticide residues, heavy metals, and residual solvents, with sealed, dry, light-protected storage supported by stability data. Labels should list all ingredients, plant part, serving amount, lot, expiry, warnings, and responsible business. “Traditional calming,” “natural,” “pharmacopoeial source,” or detection of one marker proves neither human sleep efficacy nor liver safety, and regulatory categories cannot be transferred unchanged between jurisdictions.